论文部分内容阅读
目的应用重组人生长激素(recombinant human growth hormone,rhGH)促进月经初潮时特发性矮小症(idio-pathic short stature,ISS)女童的生长发育,并观察其疗效。方法对36例月经初潮后1个月内就诊的特发性矮小症女孩,根据家长治疗意愿,分为治疗组(22例)和对照组(14例),治疗组每晚临睡前给予rhGH 0.15～0.20 IU/(kg.d)皮下注射,疗程12个月,对照组未给予任何治疗,观察时间12个月。最后比较两组儿童的骨龄(bone age,BA)、生长速率(growth velocity,GV)、预测成年身高(prediction of adult height,PAH)、身高标准差分值(HtSDSBA)。结果治疗组患儿治疗后GV、HtSDSBA、PAH与治疗前比较,差异有统计学意义(P<0.05),其他差异无统计学意义(P>0.05);治疗后治疗组GV、PAH、HtSDSBA与对照组比较,差异有统计学意义(P<0.05);两组其他指标比较,差异无统计学意义(P>0.05)。结论 rhGH能改善青春后期ISS女童PAH、GV及HtSDSBA,而BA增长无明显加速现象,无严重不良反应,疗效肯定。
Objective To investigate the effects of recombinant human growth hormone (rhGH) on the growth and development of idiopathic short stature (ISS) girls at menarche. Methods Thirty-six girls with idiopathic short stature who were treated within 1 month after menarche were divided into treatment group (n = 22) and control group (n = 14) according to parents’ willingness to treat. The patients in treatment group were given rhGH 0.15 ~ 0.20 IU / (kg.d) subcutaneous injection, the course of 12 months, the control group did not give any treatment, the observation time of 12 months. Finally, the bone age (BA), growth velocity (GV), prediction of adult height (PAH) and height standard deviation (HtSDSBA) were compared between the two groups. Results After treatment, GV, HtSDSBA and PAH in the treatment group were significantly different from those before treatment (P <0.05), but there was no significant difference in the other groups (P> 0.05). After treatment, the levels of GV, PAH, The difference between the two groups was statistically significant (P <0.05). There was no significant difference between other two groups (P> 0.05). Conclusions rhGH can improve PAH, GV and HtSDSBA in adolescent ISS girls, but there is no obvious acceleration in BA growth, no serious adverse reactions, and the curative effect is sure.